Parth Doshi · for Kathleen, Tess, and the Valthos team
I want to run Growth Ops at Valthos. Here's how I'd start.
A 180-day plan for the Growth Operations role.
Valthos · backed by
A 180-day plan for the Growth Operations role.
DTRA, JPEO-CBRND, and DARPA BTO fund the path. The existing $609K BTO grant is the foothold. JE-RDAP's 2027 recompete is the prize. Counter-bioweapon response, force protection, force readiness.
BARDA, ARPA-H, ASPR, and Project NextGen partners (Moderna, Amgen). Variant-resilient countermeasures, outbreak response, civilian-side procurement. The longer route to a multi-year program of record.
DARPA
DTRA
DIU
IARPA
UKDI
LANL
BARDA
ARPA-H
NIH
Moderna
Amgen
Thermo Fisher
Allen Institute
13+ named targets across two tracks. Full table with submission windows, sales cycles, and deal sizes lives in the funding playbook.
BTO continuation + one early commercial pilot.
Above + MCDC OTA + DIU CSO + ARPA-H ISO + one pharma anchor.
Above + BARDA invitation converts + ARPA-H ISO + multi-pharma anchor.
JE-RDAP, DTRA's $8.27B biothreat IDIQ, recompetes around 2027. DARPA OTAs and early demos are entry ramps, not endpoints. The job is converting them into the kind of program of record (JE-RDAP being the closest live shot) that doesn't unwind every cycle. The current prime pool (GDIT, Lockheed, Parsons, Perimeter) won't put a new vendor on their bid teams without named past performance to cite.
By 2027 Valthos either has 2-3 named federal task-order performances on the resume, or it doesn't. Everything in §2 through §6 is that laddering: BTO continuation, MCDC OTA, BARDA EZ-BAA, ARPA-H ISO. Each delivered award compounds into the citation the next bid uses.
Two tracks still need two different proposal stacks: NatSec/DoD biothreat capture (BTO BAAs, MCDC OTAs, JE-RDAP teaming) and HHS/civilian BD (BARDA EZ-BAA, ARPA-H ISO, Project NextGen partner discovery). Running both with one Growth Ops hire still demands sequencing. Month-one decision: weight DoD first off the BTO foothold, or build HHS past performance in parallel.
Biodefense appropriations are flat to declining in FY26. Running two federal tracks instead of one is partly a hedge against single-agency budget compression on either side.
DoD accelerated paths can close in 30 days (BTO office-wide BAA). HHS cycles run longer: BARDA EZ-BAA 6-12 months, ARPA-H ISO 12-24 months. Sequence them so delivery on one track doesn't stall capture on the other.
I grew up in a family of doctors. My aunt is an infectious disease specialist, and I spent years of my childhood shadowing her practice, learning the pathogens she treated. The movie Contagion, around the same time, convinced me this kind of work was interesting, had real-world impact, and was worth being around. That broader pull toward healthtech is what got me to start a wearable behavioral health company in high school. From there the path widened: growth equity at Stepstone Group, dual-use investing at Moonshots Capital (a seed and Series A fund where I got a real education in how federal funding actually works), and complex financial operations at Fora Travel (cross-border payments, consumer fintech, fintech partnerships) as the business scaled to $2B GMV and 10x advisors. Through every chapter the interest in biotech and defense kept compounding. Valthos is the one place I've found that brings every piece into the same room: infectious disease, biotech, defense, AI.
I'd be a real difference maker here, a 10x hire willing to do anything from ordering lunch and stocking the snacks to facilitating multi-million-dollar contract capture. Let's get on a call.
A 20-minute call. I'll come prepared with the latest read on three vehicles and a draft TechWatch quad chart for BARDA.